Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts
Portfolio Pulse from Benzinga Insights
Ionis Pharmaceuticals (NASDAQ:IONS) has received mixed evaluations from 8 analysts over the last three months, with ratings ranging from bullish to bearish. The average 12-month price target is $52.75, up 21.74% from the previous $43.33, with a high estimate of $62.00 and a low of $28.00. Analysts from firms including Piper Sandler, B of A Securities, Needham, Stifel, Goldman Sachs, and Morgan Stanley have updated their ratings and price targets, reflecting changes in market conditions and company performance. Ionis Pharmaceuticals specializes in antisense technology and has launched several drugs, including Spinraza and Qalsody. Despite a strong market position indicated by its market capitalization, the company has seen a -9.74% decline in revenue growth and has challenges with net margin, ROE, ROA, and a high debt-to-equity ratio.
January 18, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ionis Pharmaceuticals has a mixed outlook from analysts, with an updated average price target suggesting potential upside. However, financial challenges such as revenue decline and high debt could weigh on the stock.
The mixed analyst ratings and the increase in the average price target could create a neutral short-term impact on IONS stock. The positive sentiment from the raised price targets may be offset by concerns over the company's recent revenue decline and high debt-to-equity ratio. The relevance of the news is high as it directly pertains to IONS, and the importance is significant due to the potential influence on investor decisions. The confidence level is moderate, acknowledging the unpredictable nature of market reactions to analyst ratings and financial performance.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100